Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oxycodone Tamper Resistant vs OXYCONTIN in Chinese Subjects with Chronic Pain
NCT03403504Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Feb 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oxycodone in chronic pain (2 arms), sponsored by Mundipharma. Primary endpoints: Maximum Plasma Concentration up to 32 hours, Area Under the Curve to Last Measurable Concentration up to 32 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
oxycodone
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03403504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403504.